Brokerages Anticipate Abiomed, Inc. (NASDAQ:ABMD) to Post $1.05 EPS

Equities analysts expect Abiomed, Inc. (NASDAQ:ABMDGet Rating) to announce earnings per share (EPS) of $1.05 for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Abiomed’s earnings, with the lowest EPS estimate coming in at $0.98 and the highest estimate coming in at $1.15. Abiomed reported earnings of $1.10 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 4.5%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Abiomed will report full-year earnings of $4.62 per share for the current financial year, with EPS estimates ranging from $4.40 to $5.00. For the next year, analysts expect that the business will post earnings of $5.58 per share, with EPS estimates ranging from $5.28 to $6.12. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Abiomed.

Abiomed (NASDAQ:ABMDGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The medical equipment provider reported $1.16 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.07. The firm had revenue of $269.50 million for the quarter, compared to analysts’ expectations of $267.67 million. Abiomed had a net margin of 13.23% and a return on equity of 14.47%. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.24 EPS.

Several brokerages recently issued reports on ABMD. Wolfe Research began coverage on shares of Abiomed in a report on Tuesday, April 5th. They issued a “market perform” rating and a $330.00 price objective on the stock. SVB Leerink reduced their price objective on shares of Abiomed from $345.00 to $325.00 and set a “market perform” rating on the stock in a report on Friday, February 4th. Morgan Stanley reduced their price objective on shares of Abiomed from $292.00 to $275.00 and set an “underweight” rating on the stock in a report on Friday, February 4th. Finally, StockNews.com began coverage on shares of Abiomed in a report on Thursday, March 31st. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Abiomed has a consensus rating of “Hold” and an average target price of $341.80.

Shares of ABMD stock opened at $285.87 on Wednesday. The company’s 50-day moving average price is $307.13 and its 200-day moving average price is $319.17. The stock has a market cap of $13.01 billion, a price-to-earnings ratio of 96.58, a PEG ratio of 3.14 and a beta of 1.34. Abiomed has a twelve month low of $261.27 and a twelve month high of $379.30.

In related news, COO David M. Weber sold 300 shares of the company’s stock in a transaction that occurred on Monday, February 7th. The shares were sold at an average price of $300.25, for a total transaction of $90,075.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Todd A. Trapp sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, April 4th. The stock was sold at an average price of $333.00, for a total transaction of $333,000.00. Following the sale, the chief financial officer now owns 13,063 shares in the company, valued at $4,349,979. The disclosure for this sale can be found here. Insiders have sold 17,912 shares of company stock worth $5,804,526 over the last quarter. Insiders own 3.00% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ABMD. KRS Capital Management LLC acquired a new position in Abiomed in the fourth quarter valued at approximately $26,000. CWM LLC acquired a new position in Abiomed in the fourth quarter valued at approximately $29,000. Sageworth Trust Co of South Dakota acquired a new position in Abiomed in the fourth quarter valued at approximately $34,000. Ellevest Inc. boosted its holdings in Abiomed by 72.9% in the first quarter. Ellevest Inc. now owns 102 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 43 shares in the last quarter. Finally, Hall Laurie J Trustee acquired a new position in Abiomed in the fourth quarter valued at approximately $36,000. 92.03% of the stock is owned by hedge funds and other institutional investors.

Abiomed Company Profile (Get Rating)

Abiomed, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.

Recommended Stories

Get a free copy of the Zacks research report on Abiomed (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abiomed (NASDAQ:ABMD)

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.